BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Company News  |  Deals

Intercell, Merck deal

Intercell reported in its 2Q11 earnings that it received a $6 million milestone payment from Merck under an amended 2001 deal granting Merck exclusive rights to an Intercell bacterial antigen used in the V710 vaccine against Staphylococcus aureus. The milestone...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >